2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117764
    LSP4-2022 1413405-33-0 98%
    LSP4-2022 is a potent and brain-penetrant mGlu4-selective orthosteric agonist, with an EC50 of 0.11 μM. LSP4-2022 inhibits neurotransmission in cerebellar slices from wild-type but not mGlu4 receptor-knockout mice. LSP4-2022 shows pro-depressant activity.
    LSP4-2022
  • HY-117765
    RS-5773 129173-57-5 98%
    RS-5773 is a calcium channel inhibitor and a diltiazem congener. RS-5773 has antianginal effect and does not cause excessive hypotension or depression of atrioventricular conduction .
    RS-5773
  • HY-117774
    AHR-2244 hydrochloride 24677-84-7 98%
    AHR-2244 hydrochloride is a bioactive agent that acts against psychosis and anxiety. It selectively blocks CAR in mice, rats, and cats, and can reduce the lethality associated with amphetamine.
    AHR-2244 hydrochloride
  • HY-117787
    TUG-905 1390641-90-3 98%
    TUG-905 is a potent GPR40 agonist with an pEC50 value of 7.03. TUG-905 increases hypothalamic cell proliferation and survival. TUG-905 reduces body mass and increases the POMC mRNA expression.
    TUG-905
  • HY-117839
    PD-135666 134557-41-8 98%
    PD-135666 is a dipeptide inhibitor of cholecystokinin B (CCK B) receptors, binding to CCK B receptors in mouse cerebral cortex with IC50 of 0.1 nM. Its enantiomer, PD-140548, preferentially binds to CCK A receptors with IC50 of 2.8 nM in rat pancreas. PD-135666 exhibits anxiolytic effects in animal models.
    PD-135666
  • HY-117881
    CJ-15208 210236-47-8 98%
    CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics.
    CJ-15208
  • HY-117891
    Davasaicin 147497-64-1 98%
    Davasaicin (KR 25018), Capsaicin (HY-10448) derivative, is an orally active analgesic agent.
    Davasaicin
  • HY-117936
    Muscarinic agonist 1 168818-83-5 98%
    Muscarinic agonist 1, AF267, functions by alleviating cognitive impairments.
    Muscarinic agonist 1
  • HY-117952
    L 743310 187724-86-3 98%
    L 743310 is a non-peptide, selective antagonist of the human neurokinin hNK1 receptor, with high affinity for primate and cloned human hNK1 receptors and lower affinity for rodent NK1 receptors. L 743310 inhibits resiniferatoxin-induced plasma protein extravasation in guinea pig esophagus. L 743310 has a dose-dependent inhibitory effect on cisplatin-induced emesis.
    L 743310
  • HY-117955
    GMA-839 162882-76-0 98%
    GMA-839 is a selective modulator of the γ-aminobutyric acid A receptor (GABAA) with an IC50 value of 230 nM. GMA-839 exhibits potent anxiolytic-like activity, demonstrating significant dose-dependent anxiolytic effects in animal models, with an effective oral dose of 1.6 mg/kg. Significant increases in punished responding were observed in squirrel monkeys and pigeons. GMA-839 shows promise for research in the field of anxiolytics.
    GMA-839
  • HY-117957
    BMS-932481 1263871-36-8 98%
    BMS-932481 is an orally active modulator for γ-secretase, selectively reduce Aβ1-42 and Aβ1-40 production, with IC50s of 6.6 and 25.3 nM, respectively.
    BMS-932481
  • HY-117979
    Alphadolone 14107-37-0 98%
    Alphadolone is a GABAA receptor positive allosteric modulator. Alphadolone has antinociceptive effects. Alphadolone causes general anaesthesia.
    Alphadolone
  • HY-117983
    RU-505 1314206-29-5 98%
    RU-505 is an effective β-amyloid (Aβ)-fibrinogen interaction inhibitor with IC50s of 5.00 and 2.72 μM in fluorescence polarization (FP) and AlphaLISA assays, respectively. RU-505 is highly permeable to the BBB. RU-505 reduces cerebral amyloid angiopathy (CAA). RU-505 can be used for the research of Alzheimer’s disease (AD).
    RU-505
  • HY-117984
    RU 35929 111711-47-8 98%
    RU 35929 is a nootropic agent. RU 35929 enhances learning and memory.
    RU 35929
  • HY-117993
    MIND4 1639965-26-6 98%
    MIND4 is a neuroprotective thiozoline compound that inhibits the deacetylase SIRT2. MIND4 is also an inducer and activator of the nuclear factor NRF2. MIND4 can induce NRF2 activation in neurons and non-neuronal cells and reduce the production of reactive oxygen and nitrogen intermediates.
    MIND4
  • HY-118008
    Lesopitron 132449-46-8 98%
    Lesopitron (E-4424) is a 5-HT receptor agonist with potent anxiolytic-like effects. Lesopitron inhibits forskolin-stimulated adenylate cyclase activity with an IC50 value of 125 nM.
    Lesopitron
  • HY-118010
    Norfenfluramine 1886-26-6 98%
    Norfenfluramine ((±)-Norfenfluramine) is a major and brain-penetrant metabolite of Fenfluramine. Norfenfluramine can interact with 5-HT transporters to release 5-HT from neurons. Norfenfluramine displays antiepileptic effects in vivo.
    Norfenfluramine
  • HY-118022
    VU0361747 1309976-66-6 98%
    VU0361747 is a potent and selective positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4 PAM). VU0361737 has neuroprotective effect. VU0361737 significantly reverses Amphetamine-induced hyperlocomotion in vivo.
    VU0361747
  • HY-118030
    RQ-00311651 1257116-00-9 98%
    RQ-00311651 is a T-type calcium channel blocker that specifically targets the Cav3.2 isoform with a role in neuropathic and visceral pain. RQ-00311651 significantly inhibits T currents in HEK293 cells expressing human Cav3.1 or Cav3.2. RQ-00311651 also inhibited high potassium-induced calcium signaling. RQ-00311651 also inhibits antiallergic properties in rats and mice with neuropathic pain induced by spinal nerve injury or Paclitaxel (HY-B0015). Oral and intraperitoneal injection (10-20 mg/kg) inhibits Cerulein (HY-A0190)-induced acute pancreatitis and cyclophosphamide-induced cystitis in mice.
    RQ-00311651
  • HY-118048
    NAV 26 1198160-14-3 99.79%
    NAV 26 (compound 26) is a selective voltage-gated sodium channel Nav1.7 blocker with an IC50 of 0.37 μM. NAV 26 can be used for pain research.
    NAV 26
Cat. No. Product Name / Synonyms Application Reactivity